Advances in research of prostatic cancer vaccines

The prevalence of prostatic cancer increases worldwide in recent years, and its traditional therapies are faced with many difficulties. How to improve the curative effect of different therapies on prostatic cancer, especially castration-resistant prostate cancer（CRPC） by reducing their toxic and adverse effects and boosting the killing mechanism of specific cell immune system with tumor vaccines is highly concerned. The prostatic cancer vaccine, sipuleucel-T, approved by FDA in 2010, has been used in clinical practice, indicating that tumor vaccines have officially entered into the clinical treatment time from their basic and preclinical research. Prostatic cancer is characterized by its target antigen, low burden, slow growth, and can thus easily lead to specific immune reactions in prostatic cancer patients after vaccine treatment. Following is a review of the related preclinical and clinical researches on prostatic cancer vaccines, and their problems and prospects.